Portal de Periódicos da CAPES

CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma

2005; SAGE Publishing; Volume: 42; Issue: 4 Linguagem: Inglês

10.1354/vp.42-4-468

1544-2217

Cristan M. Jubala, John Wojcieszyn, V. E. Valli, David M. Getzy, Susan Fosmire, David G. Coffey, Donald Bellgrau, Jaime F. Modiano,

Immunotherapy and Immune Responses

We examined the expression of CD20 in normal canine peripheral blood mononuclear cells, normal canine spleen, and canine non-Hodgkin lymphoma (NHL) to determine the feasibility of using this antigen as a diagnostic aid and as a possible target for therapy. An antibody generated against a C-terminal (intracytoplasmic) epitope of human CD20 recognized proteins of 32-36 kd in normal and malignant canine lymphocytes. This antibody showed restricted membrane binding in a subset of lymphocytes in peripheral blood, in the B-cell regions from a normal canine spleen and lymph node, and in malignant cells from 19 dogs with B-cell NHL, but not from 15 dogs with T-cell NHL. The patterns of CD20 reactivity in these samples overlapped those seen using an antibody that recognizes canine CD79a. This anti-CD20 antibody is therefore suitable as an aid to phenotype canine NHL. In contrast, normal canine B cells were not recognized by any of 28 antibodies directed against the extracellular domains of human CD20 (including the chimeric mouse-human antibody Rituximab) or by any of 12 antibodies directed against the extracellular domains of mouse CD20. Thus, the use of CD20 as a therapeutic target will require the generation of specific antibodies against the extracellular domains of canine CD20.